<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTIONS 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): AUGUST 21, 1998
TRANSCEND THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 000-22383 04-3174575
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation or Organization) File Number) Identification No.)
640 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 374-1200
<PAGE> 2
ITEM 5. OTHER EVENTS.
On August 21, 1998, Transcend Therapeutics, Inc. (the "Company") announced
that Dr. Hector J. Gomez, President and Chief Executive Officer, and Dr. John J.
Whalen, Executive Vice President and Chief Scientific Officer, have resigned
from the Company. Dr. Gomez also resigned as a director of the Company. B.
Nicholas Harvey, Senior Vice President and Chief Financial Officer, has been
appointed President and will serve as interim Chief Executive Officer. Mr Harvey
has also been appointed to the Board of Directors of the Company.
Transcend also announced that it has appointed EVEREN Securities, Inc. as
its financial advisor to assist the Company in considering various strategic
alternatives with respect to its business. These alternatives include the
evaluation of the further development of Procysteine, acquisition of additional
technology, strategic alliances or sale or merger of the Company. There can be
no assurance that any such action will be successfully completed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSCEND THERAPEUTICS, INC.
(Registrant)
By: /s/ B. Nicholas Harvey
----------------------------------
B. Nicholas Harvey, President
